Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...